Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. Additionally we are shipping CTLA4 Proteins (69) and CTLA4 Kits (39) and many more products for this protein.
Showing 10 out of 442 products:
Human Polyclonal CTLA4 Primary Antibody for EIA, IHC (p) - ABIN951196
Liu, Liang, Gao, Pan, Chen, Wang, Xue, Zhang, Zhang: CTLA4 and CD86 gene polymorphisms and susceptibility to chronic obstructive pulmonary disease. in Human immunology 2010
Show all 5 references for ABIN951196
Rat (Rattus) Monoclonal CTLA4 Primary Antibody for EIA, FACS - ABIN119631
Lin, Hünig: Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. in European journal of immunology 2003
Show all 2 references for ABIN119631
Human Monoclonal CTLA4 Primary Antibody for FACS - ABIN1105901
Saito, Sakurai, Ohata, Kohsaka, Hashimoto, Okumura, Abe, Azuma: Involvement of CD40 ligand-CD40 and CTLA4-B7 pathways in murine acute graft-versus-host disease induced by allogeneic T cells lacking CD28. in Journal of immunology (Baltimore, Md. : 1950) 1998
Show all 2 references for ABIN1105901
Rat (Rattus) Monoclonal CTLA4 Primary Antibody for FACS - ABIN119633
Elflein, Rodriguez-Palmero, Kerkau, Hünig: Rapid recovery from T lymphopenia by CD28 superagonist therapy. in Blood 2003
Show all 2 references for ABIN119633
Human Monoclonal CTLA4 Primary Antibody for FACS - ABIN951193
Vijayakrishnan, Slavik, Illés, Greenwald, Rainbow, Greve, Peterson, Hafler, Freeman, Sharpe, Wicker, Kuchroo: An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. in Immunity 2004
Show all 2 references for ABIN951193
Mouse (Murine) Monoclonal CTLA4 Primary Antibody for FACS, Neut - ABIN4900291
Kipnis, Cardon, Avidan, Lewitus, Mordechay, Rolls, Shani, Schwartz: Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2004
Mouse (Murine) Monoclonal CTLA4 Primary Antibody for FACS - ABIN4897502
Al-Sadeq, Hamad, Abu-Elteen: Patterns of Expression of Vaginal T-Cell Activation Markers during Estrogen-Maintained Vaginal Candidiasis. in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2010
Human Polyclonal CTLA4 Primary Antibody for WB - ABIN1714514
Tamaka, Seike, Hagiwara, Sato, Ohtsu: Histamine suppresses regulatory T cells mediated by TGF-? in murine chronic allergic contact dermatitis. in Experimental dermatology 2015
Data suggest enhanced clinical benefit from combining CTLA-4 antigen blockade with poxvirus-based active immunotherapy.
up-regulated expression correlates with the tolerogenic effect of syngeneic hematopoietic stem cell transplantation
Induced Treg Cells Augment the Th17-Mediated Intestinal Inflammatory Response in a CTLA4-Dependent Manner
CTLA-4 has a regulatory T cell-intrinsic role in limiting peripheral regulatory T cell expansion and activation, and in their capacity to control conventional T cells.
The Ctla4 SNP (e2_77A/G) does not alter diabetes susceptibility, but does control mRNA alternative splicing.
Sorafenib suppressed the expression of immunosuppressive factors in MDSCs. These data indicate that combination therapy of sorafenib and anti-CTLA-4 Ab may be effective in advanced kidney cancer patients.
The co-stimulatory molecule CTLA-4 mediates in vitro differentiation of iTreg cells.
The bullseye immunological synapse formation is mediated by CTLA4, and may negatively control T-cell activation as a suppressive synapse.
this study reports that regulatory T (Treg) cells orchestrate memory T cell quiescence by suppressing effector and proliferation programs through inhibitory receptor, cytotoxic- T-lymphocyte-associated protein-4 (CTLA-4).
Short-term blockade with anti-CTLA-4 antibody in wild-type mice is sufficient to elicit follicular helper T cell generation and germinal center development. The latter occurs in a CD28 (show CD28 Antibodies)-dependent manner.
This study showed that CTLA-4 affects the expression of the key regulators of G1 phase progression in chronic lymphocytic leukaemia cells as well as in normal B lymphocytes.
There is an association between systemic inflammatory markers, oxidative stress and the cytotoxic T lymphocyte antigen-4 G-1661A GG+AG genotypes, malondialdehyde and neopterin which are the most conventional risk factors for coronary heart disease.
genetic association studies in an Egyptian population: Data suggest an SNP in the promoter region of CTLA4 (rs5742909, -318C/T) is associated with rheumatoid arthritis in the population studied; severity of the disease does not appear to be associated with this SNP.
It failed to show any association between CTLA-4 -318C/T polymorphism and the risk of malignant bone tumors.
this study shows that CTLA-4 expression in the naive Treg is decreased in preterm newborns
No significant association was found between +49A/G (rs231775), -318C/T (rs5742909), and +6230A/G (rs3087243) CTLA-4 gene polymorphisms and lymphoid malignancies.
Studies suggest that the cytotoxic T lymphocyte associated protein 4 (CTLA4) polymorphisms of the three alleles are not associated with genetic susceptibility to non-Hodgkin's lymphoma (NHL (show RTEL1 Antibodies)) risk.
Immune surveillance is an important mechanism in prevention of cancer development and inhibition of growth of tumors and metastasis. Checkpoint pathways prevent immune response through multiple methods including CTLA-4 and PD-1 (show PDCD1 Antibodies)/PD-L1 (show CD274 Antibodies) pathways.A variety of immune checkpoint inhibitors (PD-1 (show PDCD1 Antibodies)/PD-L1 (show CD274 Antibodies) and CTLA-4 inhibitors) have been studied in recurrent and metastatic head and neck cancers with encouraging efficacy
n combination with anti-PD-1 (show PDCD1 Antibodies)/PD-L1 (show CD274 Antibodies), the CTLA-4-expanded T cells are prevented from being functionally inhibited when they enter into the tumor microenvironment.
The CTLA-4 receptor was one of the first checkpoint inhibitors to be targeted with limited exploration and efficacy in sarcoma.The PD-1 (show PDCD1 Antibodies)/PD-L1 (show CD274 Antibodies) immunologic checkpoint pathway has demonstrated efficacy in many malignancies; studies are ongoing in sarcoma.
Suggest a truncated diphtheria toxin based recombinant porcine CTLA-4 fusion toxin as a novel approach for in vivo depletion of CD80 (show CD80 Antibodies)-positive cells.
The surface expression of CTLA-4 was increased in subclinical stages of paratuberculosis infection while levels of ZAP-70 (show ZAP70 Antibodies) were decreased in CD4 (show CD4 Antibodies)+ T cells of both subclinical and clinical animals, indicating a change in T cell phenotype with disease state.
These results suggested that the expression level of CTLA-4 in CD4 (show CD4 Antibodies)-positive T cells has a potentially immunosuppressive function in bovine leukemia infection.
Experimental infection with bovine viral diarrhea virus did not provide evidence ofTreg activation based on expression of FoxP3 (show FOXP3 Antibodies) and CTLA4.
This gene is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.
cytotoxic T-lymphocyte-associated protein 4 precursor
, CD152 protein
, cytotoxic T-lymphocyte protein 4
, cytotoxic T-lymphocyte protein 4 isoform CTLA4-TM
, cytotoxic T-lymphocyte-associated protein 4
, costimulatory molecule B7 receptor
, cytotoxic T lymphocyte-associated antigen 4
, CD152 antigen
, cytotoxic T-lymphocyte-associated antigen 4
, CD152 isoform
, celiac disease 3
, cytotoxic T lymphocyte associated antigen 4 short spliced form
, cytotoxic T-lymphocyte antigen 4
, cytotoxic T-lymphocyte-associated serine esterase-4
, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
, soluble form
, transmembrane form
, cytotoxic T lymphocyte-associated protein 4
, costimulatory molecule B7 receptor CD152